SARS-CoV-2 neutralizing antibodies for COVID-19: Outcomes for bamlanivimab versus bamlanivimab-etesevimab combination in a racially diverse cohort of patients with significant comorbidities

Monday, LM; Brar, I; Alangaden, G; Ramesh, MS

Monday, LM (通讯作者)，Henry Ford Hosp, Div Infect Dis, 2799 West Grand Blvd,Clara Ford Pavil,Suite 303, Detroit, MI 48202 USA.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022; 47 (9): 1438

Abstract

What Is Known and Objective Anti-spike monoclonal antibodies (MAB) including bamlanivimab (BAM) and bamlanivimab/etesevimab (BAM/E) have shown reduced......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索